| Condition/Drug characterized by... | Condition/Drug |
|---|
| delusions, hallucinations, and negative symptoms lasting for two months during a six month period | |
| monoamine reuptake inhibition activity, typically used to treat ADHD | |
| distrust and suspiciousness of others | |
| Anxious, Fearful PDs | |
| submissive and clingy behavior | |
| gradiosity and a lack of empathy secondary to low self-esteem | |
| detachment from social relationships | |
| norepinephrine reuptake inhibition activity, also used to treat ADHD | |
| norepinephrine and serotonin reuptake inhibition activity, used to treat obesity. | |
| GABA and dopamine-like effects, used to treat cataplexy | |
| non-bizarre delusion that does not interfere with normal functioning. | |
| disregard for the rights of others | |
| odd or eccentric behavior PDs | |
| sodium channel transport modification and myo-1-inositol-phosphatase inhibition activity. | |
| dopamine reuptake inhbition activity, typically used to treat narcolepsy. | |
| dramatic, emotional, erractic PDs | |
| a paradoxical effect of mood stabilizers (increased risk of) | |
| | Condition/Drug characterized by... | Condition/Drug |
|---|
| adenosine receptor antagonist activity | |
| sudden change in cognition and attention | |
| deeply ingrained stable, lifelong, inflexible and maladaptive patterns | |
| schizophrenia-like symptoms that persist after a concurrent mood disorder has been corrected. | |
| unstable interpersonal relationship and self-image | |
| hallucinations resulting from cocaine, meth, PCP, or LSD use | |
| norepinephrine reuptake inhibition activity, used to treat obesity. | |
| schizophrenia-like positive symptoms persisting for more than a day but less than a month | |
| acute discomfort in social relationships with odd thoughts and eccentric behavior | |
| perfectionism and rigidity | |
| sodium channel stabilization with a side effect profile including nausea, dizziness, and leukopenia. | |
| social inhibition and feelings of inadequacy | |
| excessive emotionality and attention-seeking behavior | |
| schizophrenia-like symptoms persisting for more than a day but less than six months | |
| gradual change in memory with agnosia, apraxia, aphasia, or loss of exec. fxning | |
| increased GABA activity with a side effect profile including alopecia, elevated LFTs, and platelet dysfunction | |
|
